title: Delamanid in the treatment of multidrug-resistant tuberculosis.
abstract: Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development. Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has received regulatory approval for treatment of adult pulmonary multidrug-resistant TB (MDR-TB) as one of only two new anti-tuberculosis drugs in the last 40 years. Lack of drug-drug interactions with major antiretrovirals and efficacy against MDR-TB allow DLM's applicability in a wide range of MDR-TB patients. Current and future efforts are focused on replacing less safe and less efficacious second-line drugs with DLM, its contribution to all-oral and/or shortened treatment regimens, and, ultimately, inclusion in a pan-TB regimen. This manuscript provides a brief review of DLM.
authors.affiliation: Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland, USA.
authors.forename: R
authors.initials: R
authors.lastname: Gupta
authors.affiliation: Sanofi US, Bridgewater, New Jersey, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: Wells
authors.affiliation: Otsuka Novel Product GmbH, Munich, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Hittel
authors.affiliation: Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland, USA.
authors.forename: J
authors.initials: J
authors.lastname: Hafkin
authors.affiliation: Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland, USA.
authors.forename: L J
authors.initials: LJ
authors.lastname: Geiter
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles